Werewolf Therapeutics, Inc. Operating Income

Quick Answer

Werewolf Therapeutics, Inc. reported Operating Income of -$60.68 million for fiscal year 2025.

Werewolf Therapeutics, Inc. Operating Income — Annual History

Fiscal Year Operating Income YoY Change
2025 -$60.68M +17.6%
2024 -$73.59M -81.7%
2023 -$40.50M +27.7%
2022 -$56.06M -11.9%
2021 -$50.09M -123.6%
2020 -$22.40M

Quarterly Operating Income

Quarter Ending Operating Income YoY QoQ
September 30, 2025 -$15.73M +8.2% +10.4%
June 30, 2025 -$17.54M +7.5% +2.5%
March 31, 2025 -$17.99M -4.8% -5.1%
September 30, 2024 -$17.12M -85.1% +9.7%
June 30, 2024 -$18.96M -212.5% -10.5%
March 31, 2024 -$17.16M -40.4% -85.5%
September 30, 2023 -$9.25M +26.2% -52.5%
June 30, 2023 -$6.07M +59.5% +50.4%
  • Werewolf Therapeutics, Inc. showed an increase of +17.6% in Operating Income compared to the prior fiscal year.
  • Over the 2020–2025 period, Werewolf Therapeutics, Inc.’s operating income has declined by 170.8% (from -$22.40 million to -$60.68 million).
  • The most recent figure is from Werewolf Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 27, 2026.
  • All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.

Last verified:

Leave a Comment